KR100209245B1 - Manufacturing method of triazole derivatives - Google Patents
Manufacturing method of triazole derivatives Download PDFInfo
- Publication number
- KR100209245B1 KR100209245B1 KR1019970001341A KR19970001341A KR100209245B1 KR 100209245 B1 KR100209245 B1 KR 100209245B1 KR 1019970001341 A KR1019970001341 A KR 1019970001341A KR 19970001341 A KR19970001341 A KR 19970001341A KR 100209245 B1 KR100209245 B1 KR 100209245B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- triazole
- alcohol
- butyl alcohol
- triazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
본 발명은 1,2,4-트리아졸을 1-[2-(2,4-디플루오르페닐)-2,3-에폭시프로필]-1H-1,2,4-트리아졸과 반응시키는데 있어서, 일반식 (R1)3R2N+X-의 화합물과 트리메틸설프옥소니움아이오다이드의 존재하에 반응시켜 플루코나졸을 얻는 트리아졸 유도체의 제조방법에 관한 것이다.The present invention reacts 1,2,4-triazole with 1- [2- (2,4-difluorophenyl) -2,3-epoxypropyl] -1H-1,2,4-triazole, The present invention relates to a method for producing a triazole derivative obtained by reacting a compound of the general formula (R 1 ) 3 R 2 N + X - with trimethylsulfonoxium iodide to obtain fluconazole.
Description
본 발명은 항진균작용을 가지며 진균감염증의 치료에 유용한 하기 화합물(1)의 트리아졸 유도체의 제조방법에 관한 것이다.The present invention relates to a process for the preparation of triazole derivatives of the following compound (1) having antifungal action and useful for the treatment of fungal infections.
1982년 1월 27일 공보된 유럽특허원 제0044605(ICI 社)에는 하기일반식의 화합물 및 그의 염 또는 금속 착화합물, 에테르 또는 에스테르가 개시되어 있다.European Patent Application 0044605 (ICI), published January 27, 1982, discloses compounds of the general formula and salts or metal complexes, ethers or esters thereof.
(식중, R1은 할로겐으로 치환되거나 비치환된 아릴기이며, Y1과 Y2는 탄소 또는 질소원자이다.)Wherein R 1 is an aryl group unsubstituted or substituted with halogen, and Y 1 and Y 2 are carbon or nitrogen atoms.
이 특허원의 특허청구범위 제7항 및 실시예 1에서 하기 화합물(2)의 1,3-비스-(1,2,4-트리아졸-1-일)-2-(2,4-디클로로페닐)-프로판-2-올이 개시되어 있다.1,3-bis- (1,2,4-triazol-1-yl) -2- (2,4-dichloro of the following compound (2) in claims 7 and Example 1 of this patent application Phenyl) -propan-2-ol is disclosed.
그러나, ICI 특허원에는 2,4-디플루오로페닐 화합물은 기술되어 있지 않다.However, no 2,4-difluorophenyl compounds are described in the ICI patent application.
상기 화합물(1)은 일반명 플루코나졸로 잘 알려져 있으며, 그 제조방법으로서 여러 가지가 특허출윈되어 있는데(유럽특허 009656, 카나다특허 1191076, 카나다 특허 1182822, 카나다특허 1170263, 영국특허 2099818, 미국특허 4404216, 스페인 특허 9502961, 스페인특허 9002961, 스페인특허 549020, 스페인특허 949684, 스페인특허 549022, 스페인특허 549021, 스페인특허 83-303244) 그중 대표적인 것은 다음과 같다.The compound (1) is well known under the common name fluconazole, and has been patented as a method for producing the same (Europe Patent 009656, Canada Patent 1191076, Canada Patent 1182822, Canada Patent 1170263, UK Patent 2099818, US Patent 4404216, Spain Patent 9502961, Spain Patent 9002961, Spain Patent 549020, Spain Patent 949684, Spain Patent 549022, Spain Patent 549021, Spain Patent 83-303244) Typical of these are as follows.
먼저 영국특허원 2099818(화이자 社), 카나다특허원 1182822와 1180076 에 기술된 방법으로서, 하기 도식 1에 나타낸 바와 같이 1-브로모-2,4-디플루오로벤젠을 그리냐드 또는 1-리튬화 중간체 형태로 전환시키고 1,3-디클로로아세톤과 반응시켜 화합물(2a)의 디할로알코올을 얻고, 화합물(2a)와 1,2,4-트리아졸을 반응시켜서 화합물(1)의 플루코나졸을 합성하거나 또는 화합물(2b)의 1,3-디트리아졸 아세톤과 반응시켜 화합물(1)을 제조하는 방법이다.First described in British Patent Application No. 2099818 (Pfizer), Canadian Patent Application Nos. 1182822 and 1180076, Grignard or 1-lithiation of 1-bromo-2,4-difluorobenzene as shown in Scheme 1 below. Converted to intermediate form and reacted with 1,3-dichloroacetone to obtain dihaloalcohol of compound (2a), and fluconazole of compound (1) was synthesized by reacting compound (2a) with 1,2,4-triazole; Or compound (1) by reacting with 1,3-ditriazole acetone of compound (2b).
그러나 1-브로모-2,4-디플루오로벤젠을 리튬화하는 과정에서 사응하는 상기의 방법에서 n-부틸리튬은 습기와 공기에 매우 민감하고 인화성이 매우 높으며 부식성이 크다. 또한 리튬화 반응이나 그리냐드 반응에서 사용하는 용매는 디에틸에테르나 테트라하이드로푸란인데, 이들 용매는 인화성이 매우 크고, 폭발성이 있어 위험하다.However, n-butyllithium is very sensitive to moisture and air, highly flammable and highly corrosive in the above-described method, which corresponds to lithiation of 1-bromo-2,4-difluorobenzene. The solvent used in the lithiation reaction or the Grignard reaction is diethyl ether or tetrahydrofuran. These solvents are extremely flammable and explosive and dangerous.
따라서 상기의 시약이나 용매는 많은 양을 취급하기에는 위험하므로, 상업적 규모의 대량생산에는 적합하지 않은 방법이다.Therefore, the above reagents and solvents are dangerous to handle a large amount, and thus are not suitable for mass production on a commercial scale.
영국특허원 2099818(화이자 社)에 기술된 방법은 하기 도식 2에 나타낸 바와 같이 1,3-디플루오로벤젠으로부터 화합물(3)의 에폭사이드, 즉 1-[2-(2,4-디플루오로페닐)-2,3-에폭시프로필]-1H-1,2,4-트리아졸을 제조하고, 염기인 K2CO3존재하에 1,2,4-트리아졸과 디메틸포름 아마이드 용매를 사용하여 90℃에서 4.5시간 반응시켜 목적화합물(1)을 합성하는 방법이다.The process described in British Patent Application No. 2099818 (Pfizer, Inc.) is the epoxide of compound (3) from 1,3-difluorobenzene, ie 1- [2- (2,4-difluoro, as shown in Scheme 2 below. Rophenyl) -2,3-epoxypropyl] -1H-1,2,4-triazole was prepared, using 1,2,4-triazole and dimethylformamide solvent in the presence of a base K 2 CO 3. It is a method of synthesize | combining target compound (1) by reacting at 90 degreeC for 4.5 hours.
이 방법은 각 단계별 합성이 비교적 용이한 장점이 있으나, 최종 단계의 반응수율이 44%로서 매우 낮은 단점이 있다This method has the advantage that the synthesis of each step is relatively easy, but the reaction yield of the final step is 44%, which is very low.
이러한 단점을 해결하기 위한 방법으로 카나다 특허원 2051281은 하기 도식 3과 같이 화합물(4a)의 할로히드린 중간체와 4-아미노 1,2,4-트리아졸을 반응시켜 화합물(4b)을 77.8%의 수율로 얻고, 이것을 NaNO2/HCl로 처리하여 탈아미노화하여 화합물(1)의 플루코나졸을 고수율(85.4%)로 얻는 방법이 개시되어 있다.In order to solve this disadvantage, Canadian Patent Application No. 2051281 reacts the halohydrin intermediate of Compound (4a) with 4-amino 1,2,4-triazole to give 77.8% of Compound (4b) as shown in Scheme 3 below. A method of obtaining in yield, which is treated with NaNO 2 / HCl to deaminoate to obtain fluconazole of compound (1) in high yield (85.4%), is disclosed.
그러나 이 방법도 마지막 단계 반응의 총 수율이 66.44%로서 그다지 양호한 방법은 되지 못하고 있다.However, this method is also not very good as the total yield of the last stage reaction is 66.44%.
또한, J Heterocyclic chem. 30권, 1405페이지, (1993)에 발표된 플루코나졸의 제법을 고찰해 보면, 하기 도식 4에 나타낸 바와 같이 중간체(3), 즉 2', 4'_디플루오로-2-(1H-1,2,4-트리아졸-1-일)아세토페논과 트리메틸 설프옥소니움 아이오다이드를 포타슘하이드록사이드 존재하에서 t-부틸알콜을 용매로 사용하여 18시간∼48시간 정도 환류시켜 목적 화합물인 플루코나졸(1)을 합성하는 방법이다.In addition, J Heterocyclic chem. Considering the preparation of fluconazole disclosed in Vol. 30, p. 1405, (1993), the intermediate (3), ie 2 ', 4'_difluoro-2- (1H-1, 2,4-triazol-1-yl) acetophenone and trimethyl sulfoxonium iodide were refluxed for 18 to 48 hours using t-butyl alcohol as a solvent in the presence of potassium hydroxide as a target compound, fluconazole It is a method of synthesizing (1).
그러나 이 방법은 반응시간이 18∼48 시간으로서 매우 길고, 목적 화합물인 플루코나졸(1)의 수율이 38%로서 앞서 설명한 영국특허원 2099818에 발표된 방법(수율=24.64%)보다는 높은 수율이지만, 여전히 수율이 낮으며, 이로 인해 제조 단가가 높은 문제점이 있다. 또한 반응 도중에 여러 가지의 부생성물이 생성되어 분리 및 정제가 까다로운 문제점이 있다.However, this method is very long as the reaction time is 18 to 48 hours, and the yield of the target compound fluconazole (1) is 38%. Yield is low, and there is a problem that the manufacturing cost is high. In addition, various by-products are generated during the reaction, which makes it difficult to separate and purify.
본 발명자들은 상기의 문제점을 해결하고자 많은 연구와 노력을 한 결과, 중간체 화합물(3)로부터 트리아졸 유도체를 제조하는 효율적인 방법을 개발하게 되었다.The present inventors have made a lot of research and efforts to solve the above problems, and have developed an efficient method for preparing triazole derivatives from the intermediate compound (3).
본 발명의 목적은 트리아졸 유도체의 제조방법을 제공하는데 있다.It is an object of the present invention to provide a process for the preparation of triazole derivatives.
본 발명을 상세히 설명하면 다음과 같다.The present invention is described in detail as follows.
본 발명은 하기 도식 5에 나타낸 바와 같이, 1,2,4-트리아졸을 화합물(3)과 반응시키는데 있어서, 일반식 (R1)3R2N+X-의 화합물과 트리메틸설프옥소니움아이오다이드 존재하에 아세토니트릴, 메틸알콜, n-프로필알콜, iso-프로필알콜, t-부틸알콜, n-부틸알콜, iso-부틸알콜 또는 이들 중 1종 이상과 물의 혼합용매 중에서 반응시켜 화합물(1)을 얻는 트리아졸 유도체의 제조방법에 관한 것이다.As shown in Scheme 5, in the reaction of 1,2,4-triazole with compound (3), a compound of the general formula (R 1 ) 3 R 2 N + X - and trimethylsulfonsonium In the presence of iodide, acetonitrile, methyl alcohol, n-propyl alcohol, iso-propyl alcohol, t-butyl alcohol, n-butyl alcohol, iso-butyl alcohol or one or more of them in a mixed solvent of water to react It relates to a method for producing a triazole derivative to obtain 1).
(식중, R1은 탄소수 1-20개의 알킬이고, R2는 탄소수 1-20개의 알킬 또는 아르알킬이며, X는 F, Cl, Br, I, 하이드록시 또는 메톡시이다.)(Wherein R 1 is alkyl having 1-20 carbons, R 2 is alkyl or aralkyl having 1-20 carbons, and X is F, Cl, Br, I, hydroxy or methoxy.)
일반식 (R1)3R2N+X-의 화합물 첨가량은 2.0∼3.5 당량, 바람직하게는 2.0∼3.7당량이다.The added amount of the compound is 2.0 to 3.5 equivalents, preferably 2.0 to 3.7 equivalents of-the formula (R 1) 3 R 2 N + X.
반응온도는 40∼130℃, 바람직하게는 45∼65℃이다.Reaction temperature is 40-130 degreeC, Preferably it is 45-65 degreeC.
반응시간은 반응온도 및 사용되는 테트라알킬 트리암모니움플로라이드, 테트라알킬 트리암모니움클로라이드, 테트라알킬 트리암모니움하이드록사이드, 테트라알킬 트리암모니움메톡사이드, 아르알킬 트리암모니움플로라이드, 아르알킬 트리암모니움클로라이드, 아르알킬 트리암모니움하이드록사이드 또는 아르알킬 트리암모니움메톡사이드의 종류 및 사용량에 따라 달라지나 2시간∼8시간 정도가 소요된다.The reaction time is the reaction temperature and the tetraalkyl triammonium fluoride used, tetraalkyl triammonium chloride, tetraalkyl triammonium hydroxide, tetraalkyl triammonium methoxide, aralkyl triammonium fluoride, aralkyl Depending on the type and the amount of triammonium chloride, aralkyl triammonium hydroxide or aralkyl triammonium methoxide, it takes about 2 to 8 hours.
일반식 (R1)3R2N+X-의 화합물은 벤질트리메틸암모니움클로라이드, 벤질트리메틸암모니움 하이드록사이드, 벤질트리메틸암모니움플로라이드, 벤질트리에틸암모니움클로라이드, 테트라부틸암모니움플로라이드, 테트라에틸암모니움플로라이드, 테트라메틸암모니움플로라이드, 테트라메틸암모니움클로라이드, 테트라부틸암모니움클로라이드, 테트라프로필암모니움클로라이드, 테트라에틸암모니움클로라이드, 세틸트리메틸암모니움클로라이드 테트라메틸암모니움하이드록사이드, 테트라부틸암모니움하이드록사이드, 테트라프로필암모니움하이드록사이드, 테트라에틸암모니움하이드록사이드 등이 있다.Compounds of the general formula (R 1 ) 3 R 2 N + X - are benzyltrimethylammonium chloride, benzyltrimethylammonium hydroxide, benzyltrimethylammonium fluoride, benzyltriethylammonium chloride, tetrabutylammonium fluoride , Tetraethylammonium fluoride, tetramethylammonium fluoride, tetramethylammonium chloride, tetrabutylammonium chloride, tetrapropylammonium chloride, tetraethylammonium chloride, cetyltrimethylammonium chloride tetramethylammonium hydroxide And tetrabutyl ammonium hydroxide, tetrapropyl ammonium hydroxide, tetraethyl ammonium hydroxide and the like.
반응에 사용되는 혼합용매는 아세토니트릴, 메틸알콜, n-프로필알콜, iso-프로필알콜, t-부틸알콜, n-부틸알콜 및 iso-부틸알콜 중 1종 이상과 물의 1:3~3:1으로 혼합하여 사용하는 것이 바람직하다.The mixed solvent used for the reaction is 1: 3-3: 1 of at least one of acetonitrile, methyl alcohol, n-propyl alcohol, iso-propyl alcohol, t-butyl alcohol, n-butyl alcohol and iso-butyl alcohol and water. It is preferable to mix and use.
실시예를 들어 본 발명을 상세히 설명하나 본 발명이 이에 한정되는 것은 아니다.The present invention will be described in detail with reference to Examples, but the present invention is not limited thereto.
[실시예 1]Example 1
[2-(2,4-디플루오로페닐)-1,3-비스(1H-1,2,4-트리아졸-1-일)-프로판-2-올의 제조][Preparation of 2- (2,4-difluorophenyl) -1,3-bis (1H-1,2,4-triazol-1-yl) -propan-2-ol]
2',4'-디플루오로-2-(1H-1,2,4-트리아졸-1-일)아세토페논(1.0g,4.481mM), 1,2.4-트리아졸(0.65g, 9.408mM) 그리고 트리메틸설프옥소니움아이오다이드(1.232g, 5.598mM)에 t-부틸알콜 15을 가하고, 테트라부틸암모니움플로라이드 3H2O(3.54g, 11.188mM)을 가하고 83℃에서 6시간 반응시키면 반응이 완결된다.2 ', 4'-difluoro-2- (1H-1,2,4-triazol-1-yl) acetophenone (1.0 g, 4.481 mM), 1,2.4-triazole (0.65 g, 9.408 mM And t-butyl alcohol 15 in trimethylsulfonoxium iodide (1.232g, 5.598mM) The reaction was completed by adding tetrabutylammonium fluoride 3H 2 O (3.54 g, 11.188 mM) and reacting at 83 ° C. for 6 hours.
반응혼합액을 감압농축시켜 용매를 제거하고 잔사에 에틸아세테이트 80와 20% 식염수 20를 가하여 5분간 교반한 후 층 분리하여 유기층을 취하고, 다시 20% 식염수 20와 포화식염수 20로 순차 세척한 유기층을 무수 MgSO4로 탈수하여 여과하고, 여액에 활성탄 0.25g을 가한 후 실온에서 30분간 교반하고 여과한다.The reaction mixture was concentrated under reduced pressure to remove the solvent, and ethyl acetate 80 was added to the residue. With 20% saline 20 After stirring for 5 minutes, the layers were separated, the organic layer was taken, and 20% brine 20 was added. With saturated saline 20 The organic layer washed sequentially with water was filtered by dehydration with anhydrous MgSO 4 , 0.25 g of activated carbon was added to the filtrate, and stirred at room temperature for 30 minutes and filtered.
여액을 감압농축하여 이소프로필 알콜 50를 가하여 용해시키고, 10로 농축하여 0∼5℃에서 2시간동안 교반하면 결정이 생성된다.Concentrate the filtrate under reduced pressure to give isopropyl alcohol 50 Dissolve by adding 10 The mixture was concentrated to and stirred at 0-5 ° C. for 2 hours to form crystals.
이 결정을 여과하여 건조하면 표제화합물(0.85g, 62%)이 얻어진다.The crystals were filtered off and dried to yield the title compound (0.85 g, 62%).
[실시예 2]Example 2
[2-(2,4-디플루오로페닐)-1,3-비스(1H-1,2,4-트리아졸-1-일)-프로판-2-올의 제조][Preparation of 2- (2,4-difluorophenyl) -1,3-bis (1H-1,2,4-triazol-1-yl) -propan-2-ol]
벤질트리메틸암모니움클로라이드(2.10g, 11.308mM)와 포타슘플로라이드 2H2O(1.065g, 11.314mM)을 아세토니트릴 20용매중에서 50∼55℃의 온도를 유지하여 1시간 교반한 후 감압농축하여 용매를 제거한다. 잔유물에 2',4'-디플루오로-2-(IH-1,2,4-트리아졸-1-일)아세토페논(1.0g, 4.481mM)과 트리 메틸설프옥소니움아이오다이드(1.232g, 5.598mM) 그리고 1,2,4-트리아졸(0.65g, 9.408mM)을 가하고, t-부틸알콜 15을 가한다음, 80℃에서 6시간 반응시키고 반응혼합액을 감압농축시켜 용매를 제거하고, 실시예 1에서의 방법에 준하여 처리하면 표제화합물(0 892g, 65%)이 얻어진다.Benzyltrimethylammonium chloride (2.10 g, 11.308 mM) and potassium fluoride 2H 2 O (1.065 g, 11.314 mM) were dissolved in acetonitrile 20 The temperature is maintained at 50 to 55 ° C. in the solvent, stirred for 1 hour, and then concentrated under reduced pressure to remove the solvent. In the residue 2 ', 4'-difluoro-2- (IH-1,2,4-triazol-1-yl) acetophenone (1.0 g, 4.481 mM) and trimethylsulfonoxium iodide ( 1.232 g, 5.598 mM) and 1,2,4-triazole (0.65 g, 9.408 mM) were added and t-butyl alcohol 15 The reaction mixture was added at 80 DEG C for 6 hours, the reaction mixture was concentrated under reduced pressure to remove the solvent, and the mixture was treated according to the method of Example 1 to obtain the title compound (0 892 g, 65%).
녹는점 (M.p) = 139,3℃Melting Point (M.p) = 139,3 ℃
1H-NMR 분석결과는 실시예 1의 결과와 동일하였다. 1 H-NMR analysis results were the same as in Example 1.
[실시예 3]Example 3
[2-(2,4-디플루오로페닐)-1,3-비스(1H-1,2,4-트리아졸-1-일)-프로판-2-올의 제조][Preparation of 2- (2,4-difluorophenyl) -1,3-bis (1H-1,2,4-triazol-1-yl) -propan-2-ol]
2',4'-디플루오로-2-(1H-1,2,4-트리아졸-1-일)아세토페논(2.0g,8.961mM)과 트리메틸설프옥소니움아이오다이드(2.465g, 11.202mM) 그리고 1,2,4-트리아졸(1.299g, 18.818mM)을 가한다음 t-부틸알콜 15와 물 10를 가하고 벤질트리메틸암모니움하이드록사이드 (40% 수용액, 8.845, 22.40mM)을 가한다.2 ', 4'-difluoro-2- (1H-1,2,4-triazol-1-yl) acetophenone (2.0 g, 8.961 mM) and trimethylsulfonoxium iodide (2.465 g, 11.202 mM) and 1,2,4-triazole (1.299 g, 18.818 mM) were added followed by t-butyl alcohol 15 And water 10 Benzyltrimethylammonium hydroxide (40% aqueous solution, 8.845 , 22.40 mM).
환류시키면서 1시간 교반하고 반응혼합액을 여과하여 불용물을 제거하고, 여액을 감압농축하여 용매를 제거한다음, 실리카겔상에서 클로로포름-메탄올(15:1)을 용출제로 사용하여 칼럼크로마토그래피법으로 분리하면 표제화합물(1.921g, 70%)이 얻어진다.The mixture was stirred for 1 hour while refluxing, the reaction mixture was filtered to remove insoluble matters, the filtrate was concentrated under reduced pressure to remove the solvent, and then separated by column chromatography on silica gel using chloroform-methanol (15: 1) as the eluent. Compound (1.921 g, 70%) is obtained.
녹는점 (M.p) = 139,7℃Melting Point (M.p) = 139,7 ℃
1H-MM 분석결과는 실시예 1의 결과와 동일하였다. 1 H-MM analysis results were the same as the results of Example 1.
[실시예 4]Example 4
[2-(2,4-디플루오로페닐)-1,3-비스(1H-1,2,4-트리아졸-1-일)-프로판-2-올의 제조][Preparation of 2- (2,4-difluorophenyl) -1,3-bis (1H-1,2,4-triazol-1-yl) -propan-2-ol]
2',4'_디플루오로-2-(1H-1,2,4-트리아졸-1-일)아세토페논(2.0g,8.961mM)과 트리메틸설프옥소니움아이오다이드(2.465g, 11.202mM) 그리고 1,2,4-트리아졸(1.20g, 17.374mM)을 t-부틸알콜 40용매중에 가하고 벤질트리메틸암모니움메톡사이드(40% 메틸알콜용액, 10.153, 22.403mM)을 가한다음 반응온도를 80∼83℃로 하여 6시간 반응시킨다.2 ', 4'_difluoro-2- (1H-1,2,4-triazol-1-yl) acetophenone (2.0 g, 8.961 mM) and trimethylsulfonoxium iodide (2.465 g, 11.202 mM) and 1,2,4-triazole (1.20 g, 17.374 mM) were added to tert-butyl alcohol 40 Benzyltrimethylammonium methoxide (40% methyl alcohol solution, 10.153) , 22.403 mM) was added and the reaction temperature was 80-83 ° C. for 6 hours.
반응완결후, 반응혼합액을 여과하여 불용물을 제거하고, 여액을 감압농축하여 용매를 제거한다음, 실시예 1에서의 방법에 준하여 처리하면 표제화합물(1.729g, 63%)이 얻어진다.After completion of the reaction, the reaction mixture was filtered to remove insoluble matters, the filtrate was concentrated under reduced pressure to remove the solvent, and then treated in accordance with the method of Example 1 to obtain the title compound (1.729 g, 63%).
녹는점 (M.p) = 139,2℃Melting Point (M.p) = 139,2 ℃
1H-NMR 분석결과는 실시예 1의 결과와 동일하였다. 1 H-NMR analysis results were the same as in Example 1.
[실시예 5]Example 5
[2-(2,4-디플루오로페닐)-1,3-비스(1H-1,2,4-트리아졸-1-일)-프로판-2-올의 제조][Preparation of 2- (2,4-difluorophenyl) -1,3-bis (1H-1,2,4-triazol-1-yl) -propan-2-ol]
2',4'-디플루오로-2-(1H-1,2,4-트리아졸-1-일)아세토페논(2.0g,8.961mM)과 트리메틸설프옥소니움아이오다이드(2.465g, 11.202mM) 그리고 1,2,4-트리아졸 (1.20g, 17,374mM)을 n-부틸알콜 20용매중에 가하고 벤질트리메틸암모니움하이드록사이드(40% 메틸알콜용액) (9,367, 22.403mM)을 가한다.2 ', 4'-difluoro-2- (1H-1,2,4-triazol-1-yl) acetophenone (2.0 g, 8.961 mM) and trimethylsulfonoxium iodide (2.465 g, 11.202 mM) and 1,2,4-triazole (1.20 g, 17,374 mM) in n-butyl alcohol 20 Benzyltrimethylammonium hydroxide (40% methyl alcohol solution) (9,367) , 22.403 mM).
환류시키면서 1.5시간 교반하고 반응혼합액을 감압농축하여 웅매를 제거한다음, 실시예 1에서의 방법에 준하여 처리하면 표제화합물 (1.770g, 64.5%)이 얻어진다.The mixture was stirred for 1.5 hours while refluxing, the reaction mixture was concentrated under reduced pressure to remove the sulphate, and then treated according to the method of Example 1 to obtain the title compound (1.770 g, 64.5%).
녹는점 (M.p) = 139,0℃Melting Point (M.p) = 139,0 ℃
1H-NMR 분석결과는 실시예 1의 결과와 동일하였다. 1 H-NMR analysis results were the same as in Example 1.
[실시예 6]Example 6
[2-(2,4-디플루오로페닐)-1,3-비스(1H-1,2,4-트리아졸-1-일)-프로판-2-올의 제조][Preparation of 2- (2,4-difluorophenyl) -1,3-bis (1H-1,2,4-triazol-1-yl) -propan-2-ol]
2',4'-디플루오로-2-(1H-1,2,4-트리아졸-1-일)아세토페논(2.0g,8.961mM)과 트리메틸설프옥소니움아이오다이드(2.465g, 11.202mM) 그리고 1,2,4-트리아졸 (1.20g, 17.374mM)을 이소부틸알콜 20용매중에 가하고 벤질트리메틸암모니움하이드록사이드 (40% 메틸알콜용액) (9,367, 22.403mM)을 가한다.2 ', 4'-difluoro-2- (1H-1,2,4-triazol-1-yl) acetophenone (2.0 g, 8.961 mM) and trimethylsulfonoxium iodide (2.465 g, 11.202 mM) and 1,2,4-triazole (1.20 g, 17.374 mM) isobutyl alcohol 20 Benzyltrimethylammonium hydroxide (40% methyl alcohol solution) (9,367) , 22.403 mM).
환류시키면서 1.5시간 교반하고 반응혼합액을 감압농축하여 용매를 제거한다음 실시예 1에서의 방법에 준하여 처리하면 표제화합물 (1.825g, 66.5%)이 얻어진다.The mixture was stirred at reflux for 1.5 hours, the reaction mixture was concentrated under reduced pressure to remove the solvent, and then treated in accordance with the method of Example 1 to obtain the title compound (1.825 g, 66.5%).
녹는점 (M.p) = 139,5℃Melting Point (M.p) = 139,5 ℃
1H-NMR 분석결과는 실시예 1의 결과와 동일하였다. 1 H-NMR analysis results were the same as in Example 1.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019970001341A KR100209245B1 (en) | 1997-01-17 | 1997-01-17 | Manufacturing method of triazole derivatives |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019970001341A KR100209245B1 (en) | 1997-01-17 | 1997-01-17 | Manufacturing method of triazole derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
KR19980066035A KR19980066035A (en) | 1998-10-15 |
KR100209245B1 true KR100209245B1 (en) | 1999-07-15 |
Family
ID=19494990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019970001341A KR100209245B1 (en) | 1997-01-17 | 1997-01-17 | Manufacturing method of triazole derivatives |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100209245B1 (en) |
-
1997
- 1997-01-17 KR KR1019970001341A patent/KR100209245B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR19980066035A (en) | 1998-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH0458474B2 (en) | ||
HU189702B (en) | Process for preparing new triazolyl-methyl-oxirane derivatives | |
US4929735A (en) | Process for the preparation of oxiranes | |
US4960911A (en) | Process for the preparation of oxiranes | |
US5336809A (en) | Process for preparing 1-fluorocyclopropyl methyl ketone | |
US5146001A (en) | Preparation of benzyl ketones and an oxirane | |
EP0162265B1 (en) | The preparation of substituted gamma butyrolactones useful as intermediates for making fungicidal imidazoles and triazoles | |
US4632999A (en) | Process for the preparation of oxiranes | |
US4992565A (en) | Preparation of oxiranes | |
KR100209245B1 (en) | Manufacturing method of triazole derivatives | |
US4988829A (en) | Process for the preparation of 2-(4-chlorophenylethyl)-2-tert.-butyl-oxirane | |
US5159089A (en) | Selective production of threo-epoxy compounds | |
KR100200246B1 (en) | Preparation method of triazole derivatives | |
KR100209246B1 (en) | Manufacturing method of triazole derivatives | |
KR100196652B1 (en) | Preparation method of triazole derivatives | |
US5194636A (en) | Preparation of benzyl ketones and an oxirane | |
EP0319960B1 (en) | Imidazole derivative | |
WO1996020181A1 (en) | Commercial process for the manufacture of fluconazole and intermediates useful in the manufacture thereof | |
CA1119179A (en) | Process for preparing n-tritylimidazole compounds | |
HU226886B1 (en) | Novel process for preparing fluconazole monohydrate | |
NO152507B (en) | PROCEDURE FOR THE PREPARATION OF PRACTICALLY PURE (Z) -1- (HALOGEN-SUBSTITUTED PHENYL) -2- (1H-IMIDAZOL-1-UL) -O- (HALOGEN-SUBSTANCED BENZYL) -ETHANONE OXIMETERS | |
KR830000634B1 (en) | How to prepare N-trityl imidazole compound | |
JP2539261B2 (en) | Imidazole derivative | |
JPS63297371A (en) | Acetylene epoxides | |
KR900007628B1 (en) | Process for the preparing imidazole derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20100121 Year of fee payment: 12 |
|
LAPS | Lapse due to unpaid annual fee |